News

For the first time in history, the world is on a path to permanently end cervical cancer. 

Anindya Dutta, MBBS, Ph.D., and colleagues have described a novel form of gene regulation that is altered in bladder cancer, leading to the boosting of a gene pathway that helps the cancer cells survive during rapid growth.

Lung cancer is a leading cause of cancer death among men and women in the United States and is among the most common cancers worldwide. However, there are some important differences in the types, causes, affects, and outcomes of lung cancer for women.

Just in time for the 50th anniversary of the O'Neal Comprehensive Cancer Center's first National Cancer Institute core grant and NCI designation, Bassel El-Rayes, M.D., joined the O'Neal Cancer Center in January 2022 to serve as the Cancer Center's new deputy director.

Looking back on the past 50 years of basic science research at the O'Neal Comprehensive Cancer Center at UAB, cancer scientists reflect on the major discoveries that have paved the way for the future of cancer care.

For more than two decades, University of Alabama at Birmingham researcher Susan Bellis, Ph.D., has studied how the addition of sialic acid to various proteins increases cancer resistance and oncogenicity.

Four days after Matthew Snowden, 38, found out his wife was pregnant with their second child, he received some news he never thought he would hear — an oral cancer diagnosis.

The University of Alabama at Birmingham’s Department of Radiology is utilizing a special technology to help with tumor ablation therapy called the NanoKnife.  

For young children, hospitals with their noises, alarms and constant bustling of people can be intimidating. For Serenity Lane, hospitals became her second home when she was diagnosed with leukemia at the age of 4.

The University of Alabama at Birmingham has been identified by Emerging Therapy Solutions as a “Program of Experience” for Chimeric antigen receptor T cell therapy.

In honor of its 50th anniversary, the O'Neal Cancer Center reflects on its history of addressing cancer health disparities in communities across Alabama, the Black Belt and beyond.

After serving as assistant to the director of the O’Neal Comprehensive Cancer Center at UAB for a total of 48 years, Joan Kemp recalls the early days of the O’Neal Cancer Center and reflects on her time working with the O’Neal Cancer Center’s first three directors.

In honor of the O’Neal Comprehensive Cancer Center’s golden anniversary, this special issue of the O'Neal Cancer Center magazine dives into the complex social and cultural history of cancer and breaks down the evolution of the major cancer treatment modalities of the past 50 years.

For many patients, a stage 4 cancer diagnosis can be crippling. Though stage 4 diagnoses look different based on the type of cancer, across the board, treatment options are generally limited and the road to potential recovery looks daunting.

Any woman can be at risk for cervical cancer, and risk increases with age. Learn about the importance of the HPV vaccine and regular screening.

Published: January 19th, 2022 The UAB O’Neal Comprehensive Cancer Center is pleased to announce that Bassel El-Rayes, M.D., will become […]

What can genetic testing tell us about people’s risk for being predisposed to hereditary cancer, and how do patients and providers respond to […]

New research from University of Alabama at Birmingham, published in the New England Journal of Medicine, suggests a gene therapy called LentiGlobin could provide a permanent cure for sickle cell disease.

Physicians with UAB Medicine, O’Neal Comprehensive Cancer Center and the University of Alabama at Birmingham Heersink School of Medicine, have launched a new Hepatic Artery Infusion Pump Program — the only program of its type in Alabama — to offer more treatment options to patients with colon or rectal cancer that has spread to the liver.

This September, the Bone Marrow Transplantation and Cell Therapy program at the UAB O’Neal Comprehensive Cancer Center is celebrating […]

The University of Alabama at Birmingham has been named a co-site on a $30 million National Institutes of Health grant to develop new or improved treatments for patients with glioblastoma, the most common and aggressive primary brain tumor in adults.

A cancer diagnosis can bring fear, anxiety, and sometimes confusion. Patients need information they can trust to make important decisions […]

Written by: Joseph D. BryantMedia contact: Adam Pope Darrell Robinson serves his neighbors in Grenada County, Mississippi, on […]

The University of Alabama at Birmingham’s Elizabeth Brown, Ph.D., has received a $3.1 million grant from the National Cancer Institute to support her investigation of the epigenetic contribution to the risk of a condition called monoclonal gammopathy of undetermined significance, known as MGUS, in African Americans. MGUS is a condition in which an abnormal protein formed within the bone marrow is found in the blood. MGUS is a precursor to multiple myeloma, the most common blood cancer affecting African Americans. Multiple myeloma is characterized by the prolonged accumulation and survival of antibody-producing tumor cells. The disease has a median survival rate of about five years.